Skip to main content
Top
Published in: Drugs 2/2009

01-12-2009 | Review Article

Does Effective Management of Sleep Disorders Reduce Cancer-Related Fatigue?

Authors: Phyllis C. Zee, MD, PhD, Sonia Ancoli-Israel

Published in: Drugs | Special Issue 2/2009

Login to get access

Abstract

Cancer and cancer therapy are often associated with symptoms such as fatigue and sleep disturbances, before, during and after therapy. These symptoms of fatigue and poor sleep often occur in parallel having a significant impact on the physical functioning of patients with cancer. A strong correlation between cancer-related fatigue (CRF) and sleep has been observed in several studies, suggesting that they may be reciprocally related. The co-clustering of these symptoms suggests that they may have similar underlying aetiology and that treatments targeting either symptom may positively affect the other. Studies examining these clusters have shown that these symptoms often co-vary together. The potential mechanisms that link the relationship between insomnia and CRF are intriguing but require further investigation. Despite the high prevalence of insomnia and the often bidirectional relationship between poor sleep and fatigue, there are limited data to support the use of sleep management interventions as a means to reduce fatigue in patients with cancer. Assessment of the available evidence across trials is complicated by different study designs, patient selection criteria, stage of cancer treatment and by the nature of the interventions studied. Improvements from baseline in both sleep parameters and CRF have been documented in a limited number of studies, including two randomized-controlled trials using cognitive behavioural therapy for insomnia (CBT-I). In contrast, the efficacy of pharmacological therapies in reducing both insomnia and CRF is largely lacking. Clearly, treating clinically significant insomnia is likely to have benefits for the patient with cancer and for those who are recovering from cancer. In particular, pharmacotherapies for insomnia, singly or in combination with CBT-I, should be evaluated in multicentre randomized clinical trials to examine their efficacy in improving sleep quality and reducing associated CRF.
Literature
1.
go back to reference Kuo HH, Chiu MJ, Liao WC, et al. Quality of sleep and related factors during chemotherapy in patients with stage I/II breast cancer. J Formos Med Assoc 2006; 105: 64–9PubMedCrossRef Kuo HH, Chiu MJ, Liao WC, et al. Quality of sleep and related factors during chemotherapy in patients with stage I/II breast cancer. J Formos Med Assoc 2006; 105: 64–9PubMedCrossRef
2.
go back to reference Kenefick AL. Patterns of symptom distress in older women after surgical treatment for breast cancer. Oncol Nurs Forum 2006; 33: 327–35PubMedCrossRef Kenefick AL. Patterns of symptom distress in older women after surgical treatment for breast cancer. Oncol Nurs Forum 2006; 33: 327–35PubMedCrossRef
3.
go back to reference Ahlberg K, Ekman T, Gaston-Johansson F. The experience of fatigue, other symptoms and global quality of life during radiotherapy for uterine cancer. Int J Nurs Stud 2005; 42: 377–86PubMedCrossRef Ahlberg K, Ekman T, Gaston-Johansson F. The experience of fatigue, other symptoms and global quality of life during radiotherapy for uterine cancer. Int J Nurs Stud 2005; 42: 377–86PubMedCrossRef
4.
go back to reference Curran SL, Beacham AO, Andrykowski MA. Ecological momentary assessment of fatigue following breast cancer treatment. J Behav Med 2004; 27: 425–44PubMedCrossRef Curran SL, Beacham AO, Andrykowski MA. Ecological momentary assessment of fatigue following breast cancer treatment. J Behav Med 2004; 27: 425–44PubMedCrossRef
5.
go back to reference Ancoli-Israel S, Liu L, Marler MR, et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 2006; 14: 201–9PubMedCrossRef Ancoli-Israel S, Liu L, Marler MR, et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 2006; 14: 201–9PubMedCrossRef
7.
go back to reference Chow E, Fan G, Hadi S, et al. Symptom clusters in cancer patients with brain metastases. Clin Oncol 2008; 20: 76–82CrossRef Chow E, Fan G, Hadi S, et al. Symptom clusters in cancer patients with brain metastases. Clin Oncol 2008; 20: 76–82CrossRef
8.
go back to reference Kim SH, Son BH, Hwang SY, et al. Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life. J Pain Symptom Manage 2008; 35: 644–55PubMedCrossRef Kim SH, Son BH, Hwang SY, et al. Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life. J Pain Symptom Manage 2008; 35: 644–55PubMedCrossRef
9.
go back to reference Okuyama T, Akechi T, Kugaya A, et al. Factors correlated with fatigue in disease-free breast cancer patients: application of the Cancer Fatigue Scale. Support Care Cancer 2000; 8: 215–22PubMedCrossRef Okuyama T, Akechi T, Kugaya A, et al. Factors correlated with fatigue in disease-free breast cancer patients: application of the Cancer Fatigue Scale. Support Care Cancer 2000; 8: 215–22PubMedCrossRef
10.
go back to reference Liu L, Fiorentino L, Natarajan L, et al. Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy. Psychooncology 2009; 18: 187–94PubMedCrossRef Liu L, Fiorentino L, Natarajan L, et al. Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy. Psychooncology 2009; 18: 187–94PubMedCrossRef
11.
go back to reference Given B, Given C, Azzouz F, et al. Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nurs Res 2001; 50: 222–32PubMedCrossRef Given B, Given C, Azzouz F, et al. Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nurs Res 2001; 50: 222–32PubMedCrossRef
12.
go back to reference Redeker NS, Lev EL, Ruggiero J. Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract 2000; 14: 275–90; discussion 91-8PubMed Redeker NS, Lev EL, Ruggiero J. Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract 2000; 14: 275–90; discussion 91-8PubMed
13.
go back to reference Dimsdale JE, Ancoli-Israel S, Ayalon L, et al. Taking fatigue seriously, II: variability in fatigue levels in cancer patients. Psychosomatics 2007; 48: 247–52PubMedCrossRef Dimsdale JE, Ancoli-Israel S, Ayalon L, et al. Taking fatigue seriously, II: variability in fatigue levels in cancer patients. Psychosomatics 2007; 48: 247–52PubMedCrossRef
14.
go back to reference Davidson JR, MacLean AW, Brundage MD, et al. Sleep disturbance in cancer patients. Soc Sci Med 2002; 54: 1309–21PubMedCrossRef Davidson JR, MacLean AW, Brundage MD, et al. Sleep disturbance in cancer patients. Soc Sci Med 2002; 54: 1309–21PubMedCrossRef
15.
go back to reference Bower JE, Ganz PA, Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med 2005; 67: 277–80PubMedCrossRef Bower JE, Ganz PA, Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med 2005; 67: 277–80PubMedCrossRef
16.
go back to reference Bower JE, Ganz PA, Aziz N, et al. Fatigue and proin-flammatory cytokine activity in breast cancer survivors. Psychosom Med 2002; 64: 604–11PubMed Bower JE, Ganz PA, Aziz N, et al. Fatigue and proin-flammatory cytokine activity in breast cancer survivors. Psychosom Med 2002; 64: 604–11PubMed
17.
go back to reference Bower JE, Ganz PA, Dickerson SS, et al. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psycho-neuroendocrinology 2005; 30: 92–100CrossRef Bower JE, Ganz PA, Dickerson SS, et al. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psycho-neuroendocrinology 2005; 30: 92–100CrossRef
18.
go back to reference Jager A, Sleijfer S, van der Rijt CC. The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator? Eur J Cancer 2008; 44: 175–81PubMedCrossRef Jager A, Sleijfer S, van der Rijt CC. The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator? Eur J Cancer 2008; 44: 175–81PubMedCrossRef
19.
go back to reference Rich T, Innominato PF, Boerner J, et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 2005; 11: 1757–64PubMedCrossRef Rich T, Innominato PF, Boerner J, et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 2005; 11: 1757–64PubMedCrossRef
20.
go back to reference Roscoe JA, Morrow GR, Hickok JT, et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 2002; 10: 329–36PubMedCrossRef Roscoe JA, Morrow GR, Hickok JT, et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 2002; 10: 329–36PubMedCrossRef
21.
go back to reference Ryan JL, Carroll JK, Ryan EP, et al. Mechanisms of cancer-related fatigue. Oncologist 2007; 12 Suppl. 1: 22–34CrossRef Ryan JL, Carroll JK, Ryan EP, et al. Mechanisms of cancer-related fatigue. Oncologist 2007; 12 Suppl. 1: 22–34CrossRef
22.
go back to reference Ancoli-Israel S, Moore PJ, Jones V. The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care (Engl) 2001; 10: 245–55CrossRef Ancoli-Israel S, Moore PJ, Jones V. The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care (Engl) 2001; 10: 245–55CrossRef
23.
go back to reference Sela RA, Watanabe S, Nekolaichuk CL. Sleep disturbances in palliative cancer patients attending a pain and symptom control clinic. Palliat Support Care 2005; 3: 23–31PubMedCrossRef Sela RA, Watanabe S, Nekolaichuk CL. Sleep disturbances in palliative cancer patients attending a pain and symptom control clinic. Palliat Support Care 2005; 3: 23–31PubMedCrossRef
24.
go back to reference Savard J, Simard S, Blanchet J, et al. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep 2001; 24: 583–90PubMed Savard J, Simard S, Blanchet J, et al. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep 2001; 24: 583–90PubMed
25.
go back to reference Roscoe JA, Kaufman ME, Matteson-Rusby SE, et al. Cancer-related fatigue and sleep disorders. Oncologist 2007; 12 Suppl. 1:35–42PubMedCrossRef Roscoe JA, Kaufman ME, Matteson-Rusby SE, et al. Cancer-related fatigue and sleep disorders. Oncologist 2007; 12 Suppl. 1:35–42PubMedCrossRef
26.
27.
go back to reference Chen ML, Chang HK. Physical symptom profiles of depressed and nondepressed patients with cancer. Palliat Med 2004; 18:712–18PubMedCrossRef Chen ML, Chang HK. Physical symptom profiles of depressed and nondepressed patients with cancer. Palliat Med 2004; 18:712–18PubMedCrossRef
28.
29.
go back to reference Stone P, Richards M, A’Hern R, et al. Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. J Pain Symptom Manage 2001; 22: 1007–15PubMedCrossRef Stone P, Richards M, A’Hern R, et al. Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. J Pain Symptom Manage 2001; 22: 1007–15PubMedCrossRef
30.
go back to reference Theobald DE. Cancer pain, fatigue, distress, and insomnia in cancer patients. Clin Cornerstone 2004; 6 Suppl. 1D: S15–21PubMedCrossRef Theobald DE. Cancer pain, fatigue, distress, and insomnia in cancer patients. Clin Cornerstone 2004; 6 Suppl. 1D: S15–21PubMedCrossRef
31.
go back to reference Weitzner MA, Moncello J, Jacobsen PB, et al. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002; 23: 337–45PubMedCrossRef Weitzner MA, Moncello J, Jacobsen PB, et al. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002; 23: 337–45PubMedCrossRef
32.
go back to reference Yennurajalingam S, Palmer JL, Zhang T, et al. Association between fatigue and other cancer-related symptoms in patients with advanced cancer. Support Care Cancer 2008; 16: 1125–30PubMedCrossRef Yennurajalingam S, Palmer JL, Zhang T, et al. Association between fatigue and other cancer-related symptoms in patients with advanced cancer. Support Care Cancer 2008; 16: 1125–30PubMedCrossRef
33.
go back to reference Carpenter JS, Storniolo AM, Johns S, et al. Randomized, double-blind, placebo-controlled crossover trials of venla-faxine for hot flashes after breast cancer. Oncologist 2007; 12: 124–35PubMedCrossRef Carpenter JS, Storniolo AM, Johns S, et al. Randomized, double-blind, placebo-controlled crossover trials of venla-faxine for hot flashes after breast cancer. Oncologist 2007; 12: 124–35PubMedCrossRef
34.
go back to reference Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 23: 6919–30PubMedCrossRef Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 23: 6919–30PubMedCrossRef
35.
go back to reference Stockler MR, O’Connell R, Nowak AK, et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol 2007; 8: 603–12PubMedCrossRef Stockler MR, O’Connell R, Nowak AK, et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol 2007; 8: 603–12PubMedCrossRef
36.
go back to reference Kangas M, Bovbjerg DH, Montgomery GH. Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol Bull 2008; 134: 700–41PubMedCrossRef Kangas M, Bovbjerg DH, Montgomery GH. Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol Bull 2008; 134: 700–41PubMedCrossRef
37.
go back to reference Fiorentino L, Ancoli-Israel S. Insomnia and its treatment in women with breast cancer. Sleep Med Rev 2006; 10: 419–29PubMedCrossRef Fiorentino L, Ancoli-Israel S. Insomnia and its treatment in women with breast cancer. Sleep Med Rev 2006; 10: 419–29PubMedCrossRef
38.
go back to reference Ancoli-Israel S. Sleep and fatigue in cancer patents. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 4th ed. Philadelphia: Saunders, 2005: 1218–24CrossRef Ancoli-Israel S. Sleep and fatigue in cancer patents. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 4th ed. Philadelphia: Saunders, 2005: 1218–24CrossRef
39.
go back to reference Minton O, Stone P, Richardson A, et al. Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev 2008; (1): CD006704 Minton O, Stone P, Richardson A, et al. Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev 2008; (1): CD006704
40.
go back to reference Minton O, Richardson A, Sharpe M, et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008; 100: 1155–66PubMedCrossRef Minton O, Richardson A, Sharpe M, et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008; 100: 1155–66PubMedCrossRef
41.
go back to reference Berger AM, Parker KP, Young-McCaughan S, et al. Sleep wake disturbances in people with cancer and their care-givers: state of the science. Oncol Nurs Forum 2005; 32: E98–126PubMedCrossRef Berger AM, Parker KP, Young-McCaughan S, et al. Sleep wake disturbances in people with cancer and their care-givers: state of the science. Oncol Nurs Forum 2005; 32: E98–126PubMedCrossRef
42.
go back to reference Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database Syst Rev 2002; (4): CD003346 Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database Syst Rev 2002; (4): CD003346
43.
go back to reference Paltiel O, Marzec-Boguslawska A, Soskolne V, et al. Use of tranquilizers and sleeping pills among cancer patients is associated with a poorer quality of life. Qual Life Res 2004; 13: 1699–706PubMedCrossRef Paltiel O, Marzec-Boguslawska A, Soskolne V, et al. Use of tranquilizers and sleeping pills among cancer patients is associated with a poorer quality of life. Qual Life Res 2004; 13: 1699–706PubMedCrossRef
44.
go back to reference Dirksen SR, Epstein DR. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. J Adv Nurs 2008; 61: 664–75PubMedCrossRef Dirksen SR, Epstein DR. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. J Adv Nurs 2008; 61: 664–75PubMedCrossRef
45.
go back to reference Espie CA, Fleming L, Cassidy J, et al. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 2008; 26: 4651–8PubMedCrossRef Espie CA, Fleming L, Cassidy J, et al. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 2008; 26: 4651–8PubMedCrossRef
46.
go back to reference Savard J, Simard S, Ivers H, et al. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol 2005; 23: 6083–96PubMedCrossRef Savard J, Simard S, Ivers H, et al. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol 2005; 23: 6083–96PubMedCrossRef
47.
go back to reference Quesnel C, Savard J, Simard S, et al. Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer. J Consult Clin Psychol 2003; 71: 189–200PubMedCrossRef Quesnel C, Savard J, Simard S, et al. Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer. J Consult Clin Psychol 2003; 71: 189–200PubMedCrossRef
48.
go back to reference Simeit R, Deck R, Conta-Marx B. Sleep management training for cancer patients with insomnia. Support Care Cancer 2004; 12: 176–83PubMedCrossRef Simeit R, Deck R, Conta-Marx B. Sleep management training for cancer patients with insomnia. Support Care Cancer 2004; 12: 176–83PubMedCrossRef
49.
go back to reference Davidson JR, Waisberg JL, Brundage MD, et al. Non-pharmacologic group treatment of insomnia: a preliminary study with cancer survivors. Psychooncology 2001; 10: 389–97PubMedCrossRef Davidson JR, Waisberg JL, Brundage MD, et al. Non-pharmacologic group treatment of insomnia: a preliminary study with cancer survivors. Psychooncology 2001; 10: 389–97PubMedCrossRef
50.
go back to reference Berger AM, Kuhn BR, Farr LA, et al. Behavioral therapy intervention trial to improve sleep quality and cancer-related fatigue. Psychooncology 2009; 18(6): 634–46PubMedCrossRef Berger AM, Kuhn BR, Farr LA, et al. Behavioral therapy intervention trial to improve sleep quality and cancer-related fatigue. Psychooncology 2009; 18(6): 634–46PubMedCrossRef
51.
go back to reference Carlson LE, Garland SN. Impact of mindfulness-based stress reduction (MBSR) on sleep, mood, stress and fatigue symptoms in cancer outpatients. Int J Behav Med 2005; 12: 278–85PubMedCrossRef Carlson LE, Garland SN. Impact of mindfulness-based stress reduction (MBSR) on sleep, mood, stress and fatigue symptoms in cancer outpatients. Int J Behav Med 2005; 12: 278–85PubMedCrossRef
52.
go back to reference Williams SA, Schreier AM. The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer. Oncol Nurs Forum 2004; 31: E16–23PubMedCrossRef Williams SA, Schreier AM. The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer. Oncol Nurs Forum 2004; 31: E16–23PubMedCrossRef
53.
go back to reference Payne JK, Held J, Thorpe J, et al. Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy. Oncol Nurs Forum 2008; 35: 635–42PubMedCrossRef Payne JK, Held J, Thorpe J, et al. Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy. Oncol Nurs Forum 2008; 35: 635–42PubMedCrossRef
54.
go back to reference Fiorentino L, McQuaid JR, Liu L, et al. Individual cognitive behavioral therapy for insomnia in breast cancer survivors: A randomized controlled crossover pilot study. Journal of the Nature and Science of Sleep 2009; in press Fiorentino L, McQuaid JR, Liu L, et al. Individual cognitive behavioral therapy for insomnia in breast cancer survivors: A randomized controlled crossover pilot study. Journal of the Nature and Science of Sleep 2009; in press
55.
go back to reference Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002; 159: 5–11PubMedCrossRef Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002; 159: 5–11PubMedCrossRef
56.
go back to reference Grossman P, Niemann L, Schmidt S, et al. Mindfulness-based stress reduction and health benefits. A meta-analysis. J Psychosom Res 2004; 57: 35–43CrossRef Grossman P, Niemann L, Schmidt S, et al. Mindfulness-based stress reduction and health benefits. A meta-analysis. J Psychosom Res 2004; 57: 35–43CrossRef
57.
go back to reference Ehsanullah RS, Galloway DB, Gusterson FR, et al. A double-blind crossover study of diazepam rectal suppositories, 5 mg and 10mg, for sedation in patients with advanced malignant disease. Pharmatherapeutica 1982; 3: 215–20PubMed Ehsanullah RS, Galloway DB, Gusterson FR, et al. A double-blind crossover study of diazepam rectal suppositories, 5 mg and 10mg, for sedation in patients with advanced malignant disease. Pharmatherapeutica 1982; 3: 215–20PubMed
58.
go back to reference Matsuo N, Morita T. Efficacy, safety, and cost effectiveness of intravenous midazolam and flunitrazepam for primary insomnia in terminally ill patients with cancer: a retrospective multicenter audit study. J Palliat Med 2007; 10: 1054–62PubMedCrossRef Matsuo N, Morita T. Efficacy, safety, and cost effectiveness of intravenous midazolam and flunitrazepam for primary insomnia in terminally ill patients with cancer: a retrospective multicenter audit study. J Palliat Med 2007; 10: 1054–62PubMedCrossRef
59.
go back to reference Kim SW, Shin IS, Kim JM, et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci 2008; 62: 75–83PubMedCrossRef Kim SW, Shin IS, Kim JM, et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci 2008; 62: 75–83PubMedCrossRef
60.
go back to reference Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000; 11: 17–22PubMedCrossRef Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000; 11: 17–22PubMedCrossRef
61.
go back to reference Grassi L, Biancosino B, Marmai L, et al. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. J Clin Psychiatry 2004; 65: 515–20PubMedCrossRef Grassi L, Biancosino B, Marmai L, et al. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. J Clin Psychiatry 2004; 65: 515–20PubMedCrossRef
62.
go back to reference Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16: 2377–81PubMed Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16: 2377–81PubMed
63.
go back to reference Morrow GR, Gillies LJ, Hickok JT, et al. The positive effect of the psychostimulant modafinil on fatigue from cancer that persists after treatment is completed [abstract no. 8012]. J Clin Oncol 2005; 23 (16 Suppl. Pt 1): 732S Morrow GR, Gillies LJ, Hickok JT, et al. The positive effect of the psychostimulant modafinil on fatigue from cancer that persists after treatment is completed [abstract no. 8012]. J Clin Oncol 2005; 23 (16 Suppl. Pt 1): 732S
64.
go back to reference Perez DG, Loprinzi CL, Barton DL, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol 2004; 2: 50–6PubMed Perez DG, Loprinzi CL, Barton DL, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol 2004; 2: 50–6PubMed
65.
go back to reference Carlson LE, Speca M, Patel KD, et al. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 2004; 29: 448–74PubMedCrossRef Carlson LE, Speca M, Patel KD, et al. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 2004; 29: 448–74PubMedCrossRef
66.
go back to reference Miller AH, Ancoli-Israel S, Bower JE, et al. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008; 26: 971–82PubMedCrossRef Miller AH, Ancoli-Israel S, Bower JE, et al. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008; 26: 971–82PubMedCrossRef
67.
go back to reference Mills PJ, Parker B, Dimsdale JE, et al. The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biological Psychology 2005; 69: 85–96PubMedCrossRef Mills PJ, Parker B, Dimsdale JE, et al. The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biological Psychology 2005; 69: 85–96PubMedCrossRef
68.
go back to reference Bruera E, Fainsinger RL, Schoeller T, et al. Rapid discontinuation of hypnotics in terminal cancer patients: a prospective study. Ann Oncol 1996; 7: 855–6PubMedCrossRef Bruera E, Fainsinger RL, Schoeller T, et al. Rapid discontinuation of hypnotics in terminal cancer patients: a prospective study. Ann Oncol 1996; 7: 855–6PubMedCrossRef
69.
go back to reference Teegarden BR, Al Shamma H, Xiong Y. 5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem 2008; 8: 969–76PubMedCrossRef Teegarden BR, Al Shamma H, Xiong Y. 5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem 2008; 8: 969–76PubMedCrossRef
70.
go back to reference De Martino G, La Regina G, La Torre F, et al. Chiral resolution and binding study of 1,3,4,14b-tetrahydro-2,10-dimethyl-2H,10H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]benzo-triazepine (10-methyl-10-azaaptazepine) and 2-methyl-1,3,4, 14b-tetrahydro-2H-pyrazino[2, 1-d]pyrrolo[1,2-b] [1,2,5]benzo-thiadiazepine 10,10-dioxide (tiaaptazepine). Farmaco 2005; 60: 931–7PubMedCrossRef De Martino G, La Regina G, La Torre F, et al. Chiral resolution and binding study of 1,3,4,14b-tetrahydro-2,10-dimethyl-2H,10H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]benzo-triazepine (10-methyl-10-azaaptazepine) and 2-methyl-1,3,4, 14b-tetrahydro-2H-pyrazino[2, 1-d]pyrrolo[1,2-b] [1,2,5]benzo-thiadiazepine 10,10-dioxide (tiaaptazepine). Farmaco 2005; 60: 931–7PubMedCrossRef
71.
go back to reference Kast RE. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 2001; 9: 469-70PubMedCrossRef Kast RE. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 2001; 9: 469-70PubMedCrossRef
Metadata
Title
Does Effective Management of Sleep Disorders Reduce Cancer-Related Fatigue?
Authors
Phyllis C. Zee, MD, PhD
Sonia Ancoli-Israel
Publication date
01-12-2009
Publisher
Springer International Publishing
Published in
Drugs / Issue Special Issue 2/2009
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11531140-000000000-00000

Other articles of this Special Issue 2/2009

Drugs 2/2009 Go to the issue

EditorialNotes

Foreword